Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
16 sept. 2024 04h15 HE
|
Novartis Pharma AG
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1Results remain...
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
15 sept. 2024 06h05 HE
|
Precede Biosciences, Inc.
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET...
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
15 sept. 2024 03h00 HE
|
MacroGenics, Inc.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
14 sept. 2024 03h00 HE
|
Immunocore Holdings plc
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
14 sept. 2024 03h00 HE
|
Sutro Biopharma, Inc.
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...
Hologram Doctor-Patient Visits Launched by West Cancer Center
13 sept. 2024 09h20 HE
|
Proto
Berkeley, CA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- West Cancer Center & Research Institute and Proto Inc. announced the first holographic doctor-patient visits at UC Berkeley’s forum on Global...
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
12 sept. 2024 16h05 HE
|
Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
12 sept. 2024 07h00 HE
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
11 sept. 2024 05h00 HE
|
Ichnos Glenmark Innovation
Preclinical data in Nature Cancer showed IGI's ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
09 sept. 2024 17h00 HE
|
Regeneron Pharmaceuticals, Inc.
Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy...